The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes

Leukemia and Lymphoma

Volumn 55, Issue 7, 2014, Pages 1538-1543

  Fabiani, Emiliano ^a   Fianchi, Luana ^a   Falconi, Giulia ^a   Boncompagni, Riccardo ^a   Criscuolo, Marianna ^a   Guidi, Francesco ^a   La Brocca, Antonella ^a   Hohaus, Stefan ^a   Leone, Giuseppe ^a   Voso, Maria Teresa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Apoptosis; BCL2L10; Myelodysplastic syndrome; Polymorphisms; Therapy related myeloid neoplasms

Indexed keywords

CYTOCHROME P450 3A4; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; PROTEIN BCL 2; PROTEIN BCL2L10; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE QUINONE 1; UNCLASSIFIED DRUG; BCL2-LIKE 10 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DETOXIFICATION; DNA REPAIR; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SINGLE NUCLEOTIDE VARIANT; THERAPY RELATED MYELOID NEOPLASM; ADOLESCENT; AMINO ACID SUBSTITUTION; BONE MARROW; DNA MUTATIONAL ANALYSIS; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; PATHOLOGY; RISK; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; BONE MARROW; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK; YOUNG ADULT;

EID: 84903479188     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.845885     Document Type: Article

References (30)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of theWorld Health Organization (WHO) classifi cation of myeloid neoplasmsand acute leukemia: rationale and important changes. Blood 2009 ; 114 :937-951
2. Hoeijmakers JH. Genome maintenance mechanisms for preventingcancer. Nature 2001; 411: 366-374.
3. Ljungman M, Lane DP. Transcription-guarding the genome bysensing DNA damage. Nat Rev Cancer 2004; 4: 727-737.
4. Knight JA, Skol AD, Shinde A, et al. Genome-wide association studyto identify novel loci associated with therapy-related myeloid leukemiasusceptibility. Blood 2009 ; 113 : 5575-5582.
5. Schulz E, Valentin A, Ulz P, et al. Germline mutations in the DNAdamage response genes BRCA1, BRCA2, BARD1 and TP53 in patientswith therapy related myeloid neoplasms. JMed Genet 2012 ; 49 :422-428.
6. Felix C A, Walker A H, Lange B J, et al. Association of CYP3A4genotype with treatment-related leukemia. Proc Natl Acad Sci USA1998 ; 95 : 13176-13181.
7. Kelly KM, Perentesis JP. Polymorphisms of drug metabolizingenzymes and markers of genotoxicity to identify patients withHodgkin ' s lymphoma at risk of treatment-related complications.Ann Oncol 2002; 13(Suppl. 1): 34-39.
8. Worrillow L J, Allan J M. Deregulation of homologous recombinationDNA repair in alkylating agent-treated stem cell clones: a possiblerole in the aetiology of chemotherapy-induced leukaemia. Oncogene2006 ; 25 : 1709-1720.
9. Voso MT, Hohaus S, Guidi F, et al. Prognostic role of glutathioneS-transferase polymorphisms in acute myeloid leukemia. Leukemia2008 ; 22 : 1685-1691.
10. Fabiani E, Leone G, Giachelia M, et al. Analysis of genome- widemethylation and gene expression induced by 5-aza-20-deoxycytidineidentifi es BCL2L10 as a frequent methylation target in acute myeloidleukemia. Leuk Lymphoma 2010; 51: 2275-2284.
11. Fabiani E, D ' Al ò F, Scardocci A, et al. Polymorphisms ofdetoxifi cation and DNA repair enzymes in myelodyplastic syndromes.Leuk Res 2009; 3: 1068-1071.
12. Voso MT, Fabiani E, D ' Al ò F, et al. Increased risk of acute myeloidleukemia due to polymorphisms in detoxifi cation and DNA repairenzymes. Ann Oncol 2007 ; 18 : 1523-1528.
13. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathioneS-transferase P1 is associated with susceptibility to chemotherapyinducedleukemia. Proc Natl Acad Sci USA 2001 ; 98 : 11592-11597.
14. Mikata R, Fukai K, Imazeki F, et al. BCL2L10 is frequentlysilenced by promoter hypermethylation in gastric cancer. Oncol Rep2010 ; 23 : 1701-1708.
15. Xu JD, Cao XX, Long ZW, et al. BCL2L10 protein regulatesapoptosis/ proliferation through diff erential pathways in gastric cancercells. JPathol 2011 ; 223 : 400-409.
16. Naoe T, Takeyama K, Yokozawa T, et al. Analysis of geneticpolymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanesepatients with therapy-related leukemia/myelodysplastic syndrome andde novo acute myeloid leukemia. Clin Cancer Res 2000; 6: 4091-4095.
17. Seedhouse C, Bainton R, Lewis M, et al. The genotype distributionof the XRCC1 gene indicates a role for base excision repair in thedevelopment of therapy-related acute myeloblastic leukemia. Blood2002 ; 100 : 3761-3766.
18. Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms ingenes involved in homologous recombination repair interact toincrease the risk of developing acute myeloid leukemia. Clin CancerRes 2004; 10: 2675-2680.
19. Zimniak P, Nanduri B, Pikuła S, et al. Naturally occurring humanglutathione S-transferase GSTP1-1 isoforms with isoleucine andvaline in position 104 diff er in enzymatic properties. Eur J Biochem1994 ; 224 : 893-899.
20. Voso MT, Fabiani E, Piciocchi A, et al. Role of BCL2L10 methylationand TET2 mutations in higher risk myelodysplastic syndromes treatedwith 5-azacytidine. Leukemia 2011 ; 25 : 1910-1913.
21. Cluzeau T, Robert G, Mounier N, et al. BCL2L10 is a predictivefactor for resistance to azacitidine in MDS and AML patients.Oncotarget 2012; 3: 490-501.
22. Mikata R, Yokosuka O, Fukai K, et al. Analysis of genes upregulatedby the demethylating agent 5-aza-2-deoxycytidine in gastric cancer celllines. Int J Cancer 2006 ; 119 : 1616-1622.
23. Inohara N, Gourley TS, Carrio R, et al. Diva, aBcl-2 homologuethat binds directly to Apaf-1 and induces BH3-independent cell death.J Biol Chem 1998 ; 273 : 32479-32486.
24. Ke N, Godzik A, Reed J C. Bcl-B, anovel Bcl-2 family memberthat diff erentially binds and regulates Bax and Bak. JBiol Chem2001 ; 20 : 12481-12484.
25. Luciano F, Krajewska M, Ortiz-Rubio P, et al. Nur77 convertsphenotype of Bcl-B, an antiapoptotic protein expressed in plasma cellsand myeloma. Blood 2007 ; 109 : 3849-3855.
26. Beverly LJ, Lockwood WW, Shah PP, et al. Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci USA2012 ; 109 : 119-126.
27. Krajewska M, Kitada S, Winter JN, et al. Bcl-B expression inhuman epithelial and nonepithelial malignancies. Clin Cancer Res2008 ; 14 : 3011-3021.
28. Beverly LJ, Varmus H. MYC-induced myeloid leukemogenesisis accelerated by all six members of the antiapoptotic BCL family.Oncogene 2009 ; 28 : 1274-1279.
29. Guillemin Y, Cornut-Thibaut A, Gillet G, et al. Characterization ofunique signature sequences in the divergent maternal protein Bcl2l10.Mol Biol Evol 2011 ; 28 : 3271-3283.
30. Fianchi L, Criscuolo M, Lunghi M, et al. Outcome of therapyrelatedmyeloid neoplasms treated with azacitidine. JHematol Oncol2012 ; 5 : 44.